Cabozanix 20MG & 60MG (Cabozanitib)
Product Name : Cabozanix(Cabozanitib)
Generic Name : Cabozanitib
Formulation : Tablet
Available Pack Size : 90’s Pot & 30’s Pot
Available Strengths : 20mg & 60mg
Registrations : Export Only
Product Information
Cabozanix (Cabozantinib) 20mg and 60mg is a multi-targeted tyrosine kinase inhibitor used to treat advanced Renal Cell Carcinoma (RCC), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), and Neuroendocrine Tumors (NET) in adult and eligible paediatric patients. It works by inhibiting multiple receptor tyrosine kinases, including VEGFR1/2/3, MET, and AXL, that drive tumour growth, angiogenesis, and metastasis. Manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Cabozanix (Cabozantinib) 20mg and 60mg
| Brand Name | Cabozanix (Cabozantinib) |
| Generic Name | Cabozantinib INN |
| Drug Class | Multi-Targeted (Pan) Tyrosine Kinase Inhibitor (VEGFR, MET, AXL, RET and others) |
| Available Strengths | 20mg and 60mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 30 Tablets per Pot and 90 Tablets per Pot |
| Primary Indication | Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Cancer, and Neuroendocrine Tumors |
| Regulatory Approvals | USFDA Approved (RCC, HCC, DTC, pNET/epNET). EMA Approved (RCC, HCC, DTC). |
| Originator Brand | Cabometyx by Exelixis, Inc. |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Status | Export Only |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Cabozanix (Cabozantinib) Works
Cabozanix contains Cabozantinib, a multi-targeted tyrosine kinase inhibitor that blocks the activity of several receptor tyrosine kinases involved in both normal cellular function and pathological processes such as tumour growth, angiogenesis, and metastasis. Its principal molecular targets include VEGFR1, VEGFR2, VEGFR3, MET, and AXL, receptors that are frequently overexpressed or dysregulated in renal, hepatic, thyroid, and neuroendocrine cancers.
By simultaneously inhibiting these pathways, Cabozantinib starves tumours of the blood supply they need to grow (anti-angiogenesis) while also interfering with the signalling that allows cancer cells to invade surrounding tissue and spread to distant sites. This dual action on both tumour vasculature and tumour cell signalling distinguishes Cabozanix from single-target therapies and underpins its activity across multiple cancer types.
Cabozanix is administered as a once-daily oral tablet, providing an accessible targeted-therapy option for patients with advanced or metastatic disease who require continuous, long-term systemic treatment.
Indications for Cabozanix (Cabozantinib)
Cabozanix (Cabozantinib) is indicated for the following conditions:
|
Advanced Renal Cell Carcinoma (RCC) For adult patients with advanced RCC, either as monotherapy following prior anti-angiogenic therapy or as a first-line treatment in combination with the immunotherapy nivolumab. |
Hepatocellular Carcinoma (HCC) For adult patients with HCC who have previously been treated with sorafenib and require a second-line systemic treatment option for advanced liver cancer. |
|
Differentiated Thyroid Cancer (DTC) For patients aged 12 years and above with locally advanced or metastatic DTC that has progressed following prior VEGFR-targeted therapy and who are ineligible for, or refractory to, radioactive iodine. |
Neuroendocrine Tumors (pNET/epNET) For previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumours in adult and paediatric patients aged 12 years and above. |
Benefits of Cabozanix (Cabozantinib) 20mg and 60mg
|
Multi-Targeted Kinase Inhibition Cabozanix inhibits VEGFR, MET, and AXL simultaneously, disrupting tumour angiogenesis and cell signalling through multiple pathways at once, an approach that can remain effective where single-target therapies fail. |
Broad Oncology Indication Range Approved across renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumours, giving oncologists a versatile targeted-therapy option across multiple difficult-to-treat cancers. |
Once-Daily Oral Dosing As a convenient once-daily tablet, Cabozanix offers an oral alternative to infusion-based cancer therapies, simplifying long-term treatment schedules for patients and caregivers. |
|
Affordable Alternative to Cabometyx Cabozanix contains the same active ingredient as Cabometyx by Exelixis, at a significantly lower cost, helping make long-term oncology treatment financially accessible for patients worldwide. |
Combination Therapy Compatible Cabozanix can be used as monotherapy or combined with nivolumab for first-line advanced RCC, giving physicians flexibility when tailoring treatment to individual patients. |
WHO-GMP and cGMP Certified Produced by Beacon Pharmaceuticals Ltd. under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Cabozanix meets consistent quality, safety, and efficacy requirements. |
How to Take Cabozanix (Cabozantinib)
Route: Oral, taken by mouth
Standard dose for Renal Cell Carcinoma: 60mg once daily as monotherapy, or 40mg once daily when used in combination with nivolumab.
Standard dose for Hepatocellular Carcinoma: 60mg once daily.
Standard dose for Differentiated Thyroid Cancer: 60mg once daily.
Standard dose for Neuroendocrine Tumors: 60mg once daily for patients aged 12 years and above weighing at least 40kg. 40mg once daily for patients aged 12 years and above weighing less than 40kg.
With food: Take on an empty stomach. Do not eat for at least 2 hours before and at least 1 hour after each dose. Swallow tablets whole with water; do not crush or chew. Avoid grapefruit and grapefruit juice during treatment.
Hepatic impairment: A reduced starting dose is recommended for patients with mild or moderate hepatic impairment. Cabozanix is not recommended for patients with severe hepatic impairment.
Renal impairment: No dose adjustment is required for mild or moderate renal impairment. Use with caution in patients with severe renal impairment; Cabozanix has not been studied in end-stage renal disease.
Strong CYP3A4 inhibitors or inducers: Dose adjustment is recommended when Cabozanix is co-administered with strong CYP3A4 inhibitors or inducers, as these significantly alter Cabozantinib plasma exposure.
Missed dose: If a dose is missed, take it as soon as remembered unless it is within 12 hours of the next scheduled dose. Never take two doses at once.
Paediatric use: Safety and efficacy have been established for patients aged 12 years and above for pNET and epNET. Safety and efficacy in other indications for patients under 18 years have not been established.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Cabozanix treatment. Your healthcare provider will monitor blood pressure for hypertension and hypertensive crisis, liver function tests, urine protein for proteinuria, and signs of bleeding, perforation, or fistula formation, which can present as severe abdominal pain, blood in the stool, or unusual bruising. Cabozanix must be discontinued at least 28 days prior to any scheduled surgery due to the risk of impaired wound healing, and should not be restarted until the surgical wound is adequately healed. Report any severe abdominal pain, unusual bleeding, or signs of infection to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Cabozanix with strong CYP3A4 inhibitors (such as ketoconazole, ritonavir, or clarithromycin), as these can significantly increase Cabozantinib exposure and the risk of toxicity. Avoid strong CYP3A4 inducers (such as rifampin, phenytoin, or St John’s Wort), as these can reduce Cabozantinib effectiveness. If co-administration cannot be avoided, dose adjustment may be required as directed by your physician.
Avoid grapefruit and grapefruit juice during treatment. Inform your physician of all medications, supplements, and herbal products you are currently taking before starting Cabozanix, and always disclose any upcoming surgical or dental procedures.
Side Effects and Precautions
|
Common Side Effects Diarrhoea Fatigue Decreased appetite and weight loss Palmar-plantar erythrodysesthesia (hand-foot syndrome) Hypertension Nausea and vomiting Stomatitis and constipation Dysphonia (voice changes) and abdominal pain |
Serious Warnings and Precautions Severe, sometimes fatal, haemorrhage (Boxed Warning). Report any unusual bleeding or bruising immediately. Gastrointestinal perforation and fistula formation (Boxed Warning). Report severe abdominal pain immediately. Arterial and venous thromboembolic events, including myocardial infarction and stroke. Hypertension and hypertensive crisis. Blood pressure must be well controlled before starting treatment. Hepatotoxicity and osteonecrosis of the jaw. Impaired wound healing. Discontinue at least 28 days before elective surgery. Not recommended during pregnancy or breastfeeding. |
Who Should Use Cabozanix (Cabozantinib)?
Cabozanix is suitable for adult patients diagnosed with advanced renal cell carcinoma, adult patients with hepatocellular carcinoma previously treated with sorafenib, adult and paediatric patients aged 12 years and above with differentiated thyroid cancer that has progressed on prior VEGFR-targeted therapy, and adult and paediatric patients aged 12 years and above with previously treated pancreatic or extra-pancreatic neuroendocrine tumours. It is prescribed by oncologists and specialist cancer physicians experienced in managing advanced malignancies. A thorough medical assessment including liver function, blood pressure, and imaging is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals Ltd.
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Cabozanix is one of Beacon’s globally recognised oncology products, offering an affordable and bioequivalent alternative to Cabometyx by Exelixis at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Cabozanix (Cabozantinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Cabozanix (Cabozantinib) from Mediaid Pharmacy?
Cabozanix represents an important treatment option for patients facing advanced renal, liver, thyroid, and neuroendocrine cancers. As the generic equivalent of Cabometyx by Exelixis, it delivers the same active ingredient, Cabozantinib, with the same multi-targeted kinase inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Cabozanix gives patients worldwide access to high-quality targeted oncology therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Cabozantinib option with worldwide delivery, Cabozanix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Cabozanix (Cabozantinib)
What is Cabozanix (Cabozantinib) used for?
Cabozanix (Cabozantinib) is a multi-targeted tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, differentiated thyroid cancer that has progressed on prior VEGFR-targeted therapy, and previously treated pancreatic or extra-pancreatic neuroendocrine tumours. It works by blocking multiple signalling pathways that drive tumour growth, blood vessel formation, and cancer spread.
How should I take Cabozanix (Cabozantinib)?
Cabozanix is taken orally once daily on an empty stomach, with no food for at least 2 hours before and 1 hour after each dose. The standard dose is 60mg once daily for most indications, or 40mg once daily when combined with nivolumab for RCC or for lower-weight paediatric NET patients. Always follow your prescribing physician’s exact instructions.
What strengths and pack sizes is Cabozanix (Cabozantinib) available in?
Cabozanix is available in 20mg and 60mg film-coated tablets, supplied in pots of 30 or 90 tablets. Your physician will determine the correct strength and pack size based on your indication, body weight, and any required dose adjustments.
Is Cabozanix the same as Cabometyx (Cabozantinib by Exelixis)?
Yes. Cabozanix is the generic equivalent of Cabometyx. Both contain the same active ingredient, Cabozantinib, in the same dosage form and strengths. Cabozanix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and delivers the same clinical benefits as Cabometyx at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Cabozanix (Cabozantinib)?
Common side effects include diarrhoea, fatigue, decreased appetite, hand-foot syndrome, hypertension, and nausea. Cabozanix carries a boxed warning for serious risks of severe haemorrhage and gastrointestinal perforation or fistula formation. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Can Cabozanix be used with other cancer medications?
Yes. Cabozanix can be used as monotherapy or in combination with nivolumab as a first-line treatment for advanced renal cell carcinoma. Strong CYP3A4 inhibitors and inducers can significantly alter Cabozantinib exposure, so always inform your physician of all medications you are taking before starting or continuing treatment.
Is Cabozanix (Cabozantinib) safe during pregnancy or breastfeeding?
No. Cabozanix is not recommended during pregnancy or breastfeeding, and it can cause foetal harm. Women of childbearing potential must use effective contraception during treatment and for a period after the final dose as advised by their physician. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Cabozanix (Cabozantinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Cabozanix (Cabozantinib) 20mg and 60mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Cabozanix (Cabozantinib) 20mg and 60mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
